P-21
Typical Dosage
1-5 mg
Administration
Injection
Half-Life
Not well characterized
Mechanism of Action
Neuroprotection|Neurogenesis and BDNF-linked research|Cognition/memory studies|Alzheimer-related models
Research Protocol Summary
Evidence Level
Human Clinical / Marketed
Typical Protocol Duration
2-6 weeks
Species Studied
Human • Mouse • Rat
Administration Schedule
Daily
Studies
Research Availability
Individual PubMed records have not been mapped for this entry yet. Use the linked PubMed search to review the current literature directly.
Related resources
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Loading approved insights…